about
Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.Baseline CD4 Count and Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provincesWhat works - reaching universal HIV testing: lessons from HPTN 071 (PopART) trial in ZambiaIncreased vulnerability of rural children on antiretroviral therapy attending public health facilities in South Africa: a retrospective cohort studyAntiretroviral therapy and early mortality in South AfricaProvision of antiretroviral therapy to children within the public sector of South Africa.HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.Temporal trends in baseline characteristics and treatment outcomes of children starting antiretroviral treatment: an analysis in four provinces in South Africa, 2004-2009.Innovative Strategies for Scale up of Effective Combination HIV Prevention Interventions in Sub-Saharan Africa.Understanding low sensitivity of community-based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South AfricaHIV-related stigma and universal testing and treatment for HIV prevention and care: design of an implementation science evaluation nested in the HPTN 071 (PopART) cluster-randomized trial in Zambia and South Africa.Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.Moderate levels of pre-therapy drug resistance (PDR) in a generalised epidemic: time for better first-line ART?Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trialIncidence of Tuberculosis amongst HIV positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 (PopART) trial in South Africa.Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women.Balancing the need to rapidly scale-up and improve clinical outcomes in antiretroviral programmes in developing countries: lessons from an Indian programmatic cohort study.Acute care - an important component of the continuum of care for HIV and tuberculosis in developing countries.Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in ZambiaDetermination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART)Retention in care and factors critical for effectively implementing antiretroviral adherence clubs in a rural district in South AfricaHIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trialDevelopment of parallel measures to assess HIV stigma and discrimination among people living with HIV, community members and health workers in the HPTN 071 (PopART) trial in Zambia and South AfricaRenal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (
P50
Q30239741-A08A471E-BF2E-4CB8-960D-973F4004024BQ30241193-936C0FD8-885F-419A-8DA4-4DC1A770A9E1Q33626374-4DEDAD4B-9FA5-4E7D-995B-33CE63C34826Q33705179-83580C8D-DD63-480D-92CC-C930D1DDC698Q33853675-235EBABD-68C0-4981-B78E-415C93F5B9CFQ34408061-9461C1B8-EE6C-452D-A105-8CC18DB8C210Q37113094-0FE09612-37FC-42DE-B08A-039B6AA25FB9Q37227197-E925128A-9749-4456-9251-E8A5E5F0F256Q37593498-8A080F77-26C4-4FAA-9F15-79BDCC787B3FQ38437420-DC677660-6359-4EA6-BEBB-6682335F966AQ38452174-F0A6F4C9-A899-456B-A13D-5D035203D9DAQ38912662-2AFFD2D5-3195-4E10-8490-891099B6B618Q39047461-47EB0661-A373-4658-B751-37935B087AE3Q39351435-8C603AE3-8D01-4B0B-86BD-F38D4116E426Q40063398-44279EE6-3B05-455A-A2A6-44BF24732BFAQ41927394-199C3965-44F1-4B18-83C4-3B6B2C502B01Q41989084-E196A166-D7DF-42F0-BBB4-347CBDDD5C9FQ44141721-CB8E6635-49B0-4B8A-A442-DEEE48999C24Q46216092-4A8A6952-56DC-43F6-9CAE-4A248238953FQ46889726-AA363DD7-26EA-46A9-91B5-9010BF5388D9Q52577961-8C0D7AB1-1B4E-4357-82E7-079F34700CD4Q56932452-19A41B93-3B7A-46FA-8D96-8B29263F190DQ89772883-5AC4B33B-8F8C-45DA-9B17-3689A7385158Q90543687-80BC32F6-9C07-40EE-9105-2B9144C9367DQ91507419-FB4DEEEC-4F92-4963-8A37-5C7195A94411Q91998452-5A74660F-B3AF-4804-9873-8362F9258898Q92961998-63DE8307-0C8D-4E3B-B99E-772E32879712
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Peter Bock
@ast
Peter Bock
@en
Peter Bock
@es
Peter Bock
@nl
Peter Bock
@sl
type
label
Peter Bock
@ast
Peter Bock
@en
Peter Bock
@es
Peter Bock
@nl
Peter Bock
@sl
prefLabel
Peter Bock
@ast
Peter Bock
@en
Peter Bock
@es
Peter Bock
@nl
Peter Bock
@sl
P106
P1153
55565770300
P21
P31
P496
0000-0003-3211-6078